Surgical Cutdown Avoids Vascular Complications in Transcatheter Aortic Valve Replacement in Calcified and Small Femoral Arteries
Background Third-generation transcatheter heart valves (THV) are predominantly implanted through a percutaneous, transfemoral access. To reduce vascular complications, we selectively performed surgical vascular access (cutdown) in patients with particular calcified or small femoral arteries. We aim to review our experience with this approach.
Methods All patients who underwent transfemoral transcatheter aortic valve replacement (TAVR) with a third-generation THV at our institution between March 2014 and April 2019 were included in the study. All available computerized tomography studies were reassessed for access vessel diameter and visual graduation of calcifications. Vascular complications are reported according to Valve Academic Research Consortium-2 criteria.
Results A total of 944 patients were included. Among them, 879 patients underwent a percutaneous access and 65 patients underwent surgical cutdown. Also, 459 Evolut R/PRO and 420 Sapien 3/ultra were implanted percutaneously and 40 Evolut R/PRO and 25 Sapien 3 were implanted with a surgical cutdown. Patients with surgical cutdown were older (80.0 ± 7.5 vs. 83.8 ± 7.5 years, p < 0.001), had smaller femoral arteries (8.0 ± 1.6 vs. 7.6 ± 1.6 mm, p = 0.034) and more severe vessel calcifications (17.5 vs. 1.0%, p < 0.001). Procedure time was similar for cutdown and percutaneous access (64.0 vs. 64.5 minutes, p = 0.879). With percutaneous access, 80 major vascular complications (10%) occurred, whereas with surgical cutdown, no major vascular complications occurred (p < 0.005). No wound infection occurred after surgical cutdown. The mean length of stay was 8 days in both groups.
Conclusion Surgical cutdown for vascular access avoids vascular complications in patients with small or severely calcified femoral arteries.
Keywordsheart valve - transapical - percutaneous - aortic valve and root - artery/arteries (includes all peripheral arteries)
Sources of Funding
# Both authors contributed equally.
Received: 27 September 2020
Accepted: 14 January 2021
24 March 2021 (online)
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 Vora AN, Rao SV. Percutaneous or surgical access for transfemoral transcatheter aortic valve implantation. J Thorac Dis 2018; 10 (Suppl. 30) S3595-S3598
- 2 Beckmann A, Meyer R, Lewandowski J, Frie M, Markewitz A, Harringer W. German Heart Surgery Report 2017: the annual updated registry of the German Society for Thoracic and Cardiovascular Surgery. Thorac Cardiovasc Surg 2018; 66 (08) 608-621
- 3 Holmes Jr. DR, Nishimura RA, Grover FL. et al; STS/ACC TVT Registry. Annual outcomes with transcatheter valve therapy: from the STS/ACC TVT registry. J Am Coll Cardiol 2015; 66 (25) 2813-2823
- 4 Van Mieghem NM, Tchetche D, Chieffo A. et al. Incidence, predictors, and implications of access site complications with transfemoral transcatheter aortic valve implantation. Am J Cardiol 2012; 110 (09) 1361-1367
- 5 Kappetein AP, Head SJ, Généreux P. et al; Valve Academic Research Consortium-2. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Thorac Cardiovasc Surg 2013; 145 (01) 6-23
- 6 Dencker D, Taudorf M, Luk NH. et al. Frequency and effect of access-related vascular injury and subsequent vascular intervention after transcatheter aortic valve replacement. Am J Cardiol 2016; 118 (08) 1244-1250
- 7 Ruge H, Burri M, Erlebach M, Lange R. Access site related vascular complications with third generation transcatheter heart valve systems. Catheter Cardiovasc Interv 2020; (e-pub ahead of print). DOI: 10.1002/ccd.29095.
- 8 Cardounel A, Gleason TG, Lee JS. et al. Surgical cut down for vascular access with conscious sedation for transcatheter aortic valve replacement: the best of both worlds?. Interact Cardiovasc Thorac Surg 2018; 27 (04) 494-497
- 9 Barbanti M, Capranzano P, Ohno Y. et al. Comparison of suture-based vascular closure devices in transfemoral transcatheter aortic valve implantation. EuroIntervention 2015; 11 (06) 690-697
- 10 Power D, Schäfer U, Guedeney P. et al. Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVO-3 randomized trial. Catheter Cardiovasc Interv 2019; 93 (07) 1374-1381
- 11 Ruge H, Erlebach M, Mayr P, Bleiziffer S, Lange R. Clinical experience with a novel large bore vascular closure device after transfemoral transcatheter aortic valve replacement. EuroIntervention 2020; 16 (03) 262-265
- 12 Wood DA, Krajcer Z, Sathananthan J. et al; SAFE MANTA Study Investigators. Pivotal clinical study to evaluate the safety and effectiveness of the MANTA percutaneous vascular closure device. Circ Cardiovasc Interv 2019; 12 (07) e007258